ClinicalTrials.gg
Active, not recruitingNCT07286682Updated Jul 24, 2026

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB5285 in Healthy Study Participants

A Phase 1 interventional study of UCB5285 and Placebo in Healthy Participants, sponsored by UCB Biopharma SRL. Active, not recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and tolerability of single ascending doses of UCB5285 in healthy study participants, including healthy Japanese study participants

02

Conditions studied

  • Healthy Participants

Keywords

  • UCB5285
03

In context

Lead sponsor

UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 17 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For study participants of Japanese origin: study participant who is born in Japan and of Japanese descent as evidenced in appearance and verbal confirmation of familial heritage with all 4 grandparents and both parents born in Japan and has not had a significant change in lifestyle or diet since leaving Japan
  • For all study participants:
  • Study participant must be 18 to 55 years of age, inclusive, at the time of signing the
  • Study participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
  • Body weight within 40 kilograms (kg) to 110 kg and (BMI) within the range of 18 kilograms per meter square (kg/m2) to 30 kg/m2 (inclusive)

Exclusion criteria

Exclusion Criteria:

  • Study participant has a history or presence of any medical or psychiatric condition, physical examination finding, laboratory test result, (ECG), or vital sign that, in the opinion of the investigator, could significantly alter the absorption, or elimination of drugs; constitute a risk when taking the study intervention; or interfere with the interpretation of data
  • Study participant has a recent history (within 6 months of Screening) or currently active bacterial, fungal, endoparasite, or viral infection.
  • Study participant has a significant allergy to humanized monoclonal antibody (mAbs)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Participants randomized to this arm will receive a single dose of UCB5285 (Dose 1) or placebo via Route of Administration 1.

    Drug: UCB5285 · Other: Placebo

  • Experimental
    Cohort 2

    Participants randomized to this arm will receive a single dose of UCB5285 (Dose 2) or placebo via Route of Administration 1.

    Drug: UCB5285 · Other: Placebo

  • Experimental
    Cohort 3

    Participants randomized to this arm will receive a single dose of UCB5285 (Dose 3) or placebo via Route of Administration 1.

    Drug: UCB5285 · Other: Placebo

  • Experimental
    Cohort 4

    Participants randomized to this arm will receive a single dose of UCB5285 (Dose 4) or placebo via Route of Administration 1.

    Drug: UCB5285 · Other: Placebo

  • Experimental
    Cohort 5

    Participants randomized to this arm will receive a single dose of UCB5285 (Dose 4) or placebo Route of Administration 2.

    Drug: UCB5285 · Other: Placebo

  • Experimental
    Cohort 6

    Participants randomized to this arm will receive a single dose of UCB5285 (Dose 5) or placebo via Route of Administration 1.

    Drug: UCB5285 · Other: Placebo

  • Experimental
    Cohort 7

    Participants randomized to this arm will receive a single dose of UCB5285 (Dose 5) or placebo via Route of Administration 2.

    Drug: UCB5285 · Other: Placebo

  • Experimental
    Cohort 8

    Participants randomized to this arm will receive a single dose of UCB5285 (Dose 6) or placebo via Route of Administration 1.

    Drug: UCB5285 · Other: Placebo

Interventions

  • DrugUCB5285

    Participants will receive UCB5285 as prespecified in each cohort.

  • OtherPlacebo

    Participants will receive matching placebo as prespecified in each cohort.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (TEAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment emergent adverse events (TEAEs) are adverse events that are not present prior to the pharmaceutical product administration or an already present event that worsens either in intensity or frequency.

    Time frame: From Day 1 to the End Of Study (up to Day 161)

  2. Incidence of Treatment-Emergent Serious Adverse Events (SAEs)

    An SAE is defined as any untoward medical occurrence that, at any dose, meets 1 or more of the criteria listed: * Results in death * Is life-threatening * Requires inpatient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect * Other important medical events which based on medical or scientific judgement may jeopardize the patients or may require medical or surgical intervention to prevent any of the above.

    Time frame: From Day 1 to the End Of Study (up to Day 161)

Secondary outcomes

  1. Maximum Observed Serum Concentration (Cmax) of UCB5285

    Maximum observed serum concentration (Cmax) of UCB5285

    Time frame: From Day 1 (Predose) at predefined time points up to Day 161

  2. Area Under the Serum Concentration-Time Curve From Time Zero to Infinity (AUC) of UCB5285

    Area under the serum concentration-time curve from time zero to infinity (AUC) of UCB5285

    Time frame: From Day 1 (Predose) at predefined time points up to Day 161

  3. Area Under the Serum Concentration-Time Curve from Time Zero to the Time of Last Detectable Concentration (AUC0-t) of UCB5285

    Area under the serum concentration-time curve from time zero to the time of last detectable concentration (AUC0-t) of UCB5285

    Time frame: From Day 1 (Predose) at predefined time points up to Day 161

07

Study locations

1 site
  • Up0161 1001
    Harrow, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — Due to the small sample size in this trial, individual participant-level data cannot be adequately anonymized as there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2025
First posted
Dec 16, 2025
StartActual
Dec 8, 2025
Primary completionEst.
Dec 13, 2026
CompletionEst.
Dec 13, 2026
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07286682
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Dec 16, 2025
Start date
Dec 8, 2025
Primary completion
Dec 13, 2026 (estimated)
Completion
Dec 13, 2026 (estimated)
Last update
Jul 24, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273 (UCB)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion